ARTICLE

With an ever-increasing emphasis on minimizing drug candidate attrition, scientists are focusing on target safety at earlier points in the research process.

In this exclusive interview, Drug Target Review spoke with Dr. Gordon Baxter, Chief Scientific Officer of Instem, to learn how target safety assessments can enable researchers to quickly identify and assess unintended adverse consequences of potential treatments before an expensive investment is made.